Related Experiment Video
Updated: Jun 11, 2026
09:38
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
Non-clinical models: validation, study design and statistical consideration in safety pharmacology
M K Pugsley1, R Towart, S Authier
1Department of Toxicology/Pathology, Johnson & Johnson PRD, Raritan, NJ 08869, United States. mpugsle2@its.jnj.com
Journal of Pharmacological and Toxicological Methods
|July 6, 2010
Summary
This special issue details non-clinical safety pharmacology methods for assessing new chemical entities before human trials. It highlights advancements in surgical techniques, data analysis, and study designs for robust drug safety evaluation.
Area of Science:
- Pharmacology
- Toxicology
- Drug Development
Background:
- This special issue of the Journal of Pharmacological and Toxicological Methods (JPTM) is dedicated to safety pharmacology methods, marking the 7th consecutive year of coverage.
- It focuses on non-clinical methods and models for assessing the safety profile of new chemical entities (NCEs) before first-in-human (FIH) studies.
Discussion:
- Industry and Contract Research Organizations (CROs) have collaborated to publish detailed surgical methods, standard, and integrated study designs for drug safety assessment.
- These special issues aim to validate core battery and secondary drug safety assessment methods used in drug development programs.
- The journal serves as a key forum for presenting novel and modified safety pharmacology methods to the scientific community.
Key Insights:
- The current issue introduces advanced surgical methods and innovative data capture and analysis techniques.
- Improvements in study design and the use of positive control compounds with known activity are also featured.
- This collection emphasizes the practical application of these methods for determining drug safety.
Outlook:
- Continued focus on refining and validating safety pharmacology methods is crucial for ensuring drug safety.
- Integration of novel techniques in data analysis and study design will enhance the predictive power of non-clinical assessments.
- This ongoing series in JPTM supports the global effort to improve the safety evaluation of new therapeutics.
Related Concept Videos
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...